Blood Res.  2024;59:39. 10.1007/s44313-024-00041-7.

How to improve AML outcomes?

• Tan T
• Bozdag S

• KMID: 2562541
• DOI: http://doi.org/10.1007/s44313-024-00041-7

Abstract

Understanding the intricacies of the pathophysiology and genomic landscape has enhanced the long-term outcomes for patients with acute myeloid leukemia (AML). The identification of novel molecular targets has introduced new therapeutic strategies that attempt to surpass the dominance of the "7 + 3 regimen" established in the 1970s. In 2022, the World Health Organization and International Consensus Classification revised their definitions and approaches to AML, reflecting the current and evolving changes at the molecular level. The guidelines are now grounded in a definition of the disease that emphasizes genetic characteristics. Today, we recognize AML as a genetically diverse disease; a retrospective study identified 5234 driver mutations across 76 genes or genomic regions, with two or more drivers observed in 86% of patients (Papaemmanuil et al., N Engl J Med 374:2209–21, 2016).

Keyword

AML; Treatment; Relapsed; Targeted; Mutations; Outcome